Immunoglobulin E specific for Dermatophagoides farinae group 2 allergen (Der f 2) (Der f 2-specific IgE)

Immunoglobulin E (IgE) antibodies specific for the Dermatophagoides farinae group 2 (Der f 2) allergen are central mediators of the allergic response to house dust mites (HDM). Der f 2 is a major 14-kDa protein allergen from the American house dust mite, characterized by high IgE-binding prevalence in sensitized individuals (UniProt: P49278). These specific IgE molecules bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon re-exposure to Der f 2, the allergen cross-links the IgE-receptor complexes, triggering the release of inflammatory mediators like histamine and leukotrienes, which cause the symptoms of allergic asthma, rhinitis, and atopic dermatitis (PubMed: 29351916, PubMed: 24304361). Therapeutic strategies targeting this pathway include the anti-IgE monoclonal antibody Omalizumab, which sequesters free IgE to prevent receptor binding and downregulates FcεRI expression (PubMed: 21457114). Alternatively, allergen immunotherapy (AIT) using Dermatophagoides farinae extracts aims to desensitize the patient by shifting the immune response toward regulatory T cells and producing IgG4 blocking antibodies that compete with IgE for allergen binding (PubMed: 28212938).

Other names

Anti-Der f 2 IgEsIgE to Der f 2Dermatophagoides farinae allergen 2-specific IgEHouse dust mite-specific IgEIgE specific for Der f 2

Monoclonal antibodies like Omalizumab neutralize circulating IgE and prevent binding to FcεRI receptors on mast cells and basophils (PubMed: 21457114). Allergen immunotherapy (AIT) induces immune tolerance by promoting the production of allergen-specific IgG4 blocking antibodies and regulatory T cells (PubMed: 28212938).